The company

Established in 1997, Phlexglobal delivers a specialist service across the pharmaceutical, biotechnology, medical device and healthcare industries. The company offers a support service for all administrative and operational aspects of the clinical trial process, ranging from document management, ethics committee submission, pre and post inspection support to tracking systems support, archiving and training.

Phlexglobal’s main area of expertise is in the management of Trial Master File (TMF) projects. A TMF is the collection of all of the essential documents required to demonstrate the compliance with the applicable regulatory requirements involved in a clinical trial. In 2006, Phlexglobal developed its own electronic system, or eTMF, called PhlexEview, which combined with the related services of scanning and archiving, is now the principal thrust of the business.

Employing c.200 people in the UK and US, Phlexglobal has relationships with most of the top ten global pharmaceutical companies. The pipeline is impressive, including most of the remaining top fifty.

The investment

Richard Swann, Nicola Boyd and Charles Thompson led the transaction at Inflexion, with Richard and Nicola both joining the Board as Non Executive Directors.

Phlexglobal operates in an interesting niche market and is an excellent example of the type of business that Inflexion seeks to invest in, offering a superior service and product to its customers.